Napredna pretraga

Pregled bibliografske jedinice broj: 321828

Methylentetrahydrofolate reductase polymorphism and susceptibility to prostate cancer


Šimundić, Ana-Maria; Reljić, Ante; Nikolac, Nora; Justinić, Danijel; Kraus, Ognjen
Methylentetrahydrofolate reductase polymorphism and susceptibility to prostate cancer // European Urology Meetings
Zagreb, Hrvatska, 2007. (poster, sažetak, znanstveni)


Naslov
Methylentetrahydrofolate reductase polymorphism and susceptibility to prostate cancer

Autori
Šimundić, Ana-Maria ; Reljić, Ante ; Nikolac, Nora ; Justinić, Danijel ; Kraus, Ognjen

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
European Urology Meetings / - , 2007

Skup
EAU 7th Central European Meeting

Mjesto i datum
Zagreb, Hrvatska, 26.-27.9.2007.

Vrsta sudjelovanja
Poster

Vrsta recenzije
Neobjavljeni rad

Ključne riječi
MTHFR; prostate cancer

Sažetak
Introduction & Objectives: Methylentetrahydrofolate reductase (MTHFR) is the most important enzyme involved in DNA methylation process and converts 5, 10-methyltetrahydrofolate to 5-methyltetrahydrofolate. The C677T polymorphism of the MTHFR gene is associated with 70% lower enzyme activity and hypomethylation. many studies investigated the role of MTHFR polymorphism in cancer susceptibility and though most authors report lower frequency of mutated T allele in cancer patients, results are still inconclusive. The aim of this studa was to asses the frequency distribution of mutated T allele in the patients with prostatic cancer (PC) and benign prostatic hyperplasia (BPH). material & methods: The case control study comprised of 45 patients with BPH and 95 patients with prostatic cancer. For the patients with carcinoma, Gleason score was determined as an index of degree of malignancy. PCR-RFLP method was used to determine MTHFR C677T polymorphism. Results: Genotypes in both groups were in Hardy-Weinberg equilibrium. Proportions of genotypes in PC group were C/C=0.40, C/T=0.51 and T/T=0.09 and in the BPH group C/C=0.47, C/T=0.42 and T/T=0.11. There was no statistically significant difference in genotype distribution between groups (P=0.6558). Odds ratio and 95% confidence interval for the C/T genotype was 1.3961(0.658-2.963) and for the T/T genotype 0.9947(0.295-3-357). Proportions in the group of patients with prostatic cancer of lower malignancy (Gleason score 4-6) were C/C=0.39, C/T=0.47 and T/T=0.14 ; and in the group with more malignant prostatic cancer (Gleason score 7-9) C/C=0.40, C/T=0.53 and T/T=0.07. Proportions between groups with higher and lower malignancy were not different (P=0.8693). Conclusions: results of our research didn't provide any evidence for the association of MTHFR C677T polymorphism with prostate cancer risk.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Projekt / tema
134-1340227-0200 - Upala i udio farmakogenetike u razvoju i ishodu akutnih i kroničnih bolesti (Ana-Maria Šimundić, )

Ustanove
KBC "Sestre Milosrdnice"